is compounding tirzepatide going away FDA Ban on Compounded GLP-1 Drugs: What to Know September 2, 2025: U.S. compounding

Among these, tirzepatide, a long-acting dual GLP-1R/GIPR agonist approved for diabetes and obesity, shows enhanced therapeutic outcomes on cardiometabolic diseases compared to selective GLP-1R agonists (20, 33, 34)

This can cause: Blurred vision Worsening eyesight over time Objects that look wavy or curved Faded colors Loss of vision in the center of your eyesight Some people with DME have mild or no symptoms, but these can get worse over time

If access or affordability is an obstacle, speak to your LeanMD physician about options, including dose adjustments or transition planning

Many insurance providers will cover the cost of prescription drugs, including those for weight management

Noticing palpitations leads to anxiety, which raises the activity of the nervous system, which can, in turn, make episodes more noticeable or more frequent